Overview

Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)

Status:
Terminated
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and tolerability of repeated subcutaneous (SC) doses of belimumab in subjects with SLE.
Phase:
Phase 2
Details
Lead Sponsor:
Human Genome Sciences Inc.
Collaborator:
GlaxoSmithKline
Treatments:
Belimumab